Business Wire

GSMA

Share
5G To Power Economic Growth in Europe, Finds GSMA Study

Europe’s mobile ecosystem is forecast to account for more than 4 per cent of the region’s GDP by 2022, but the right regulatory action must be taken to position Europe as a global 5G leader and establish a genuine EU Digital Single Market, according to a new report published by the GSMA today. The latest regional edition of the GSMA’s flagship Mobile Economy series was released today at the GSMA Mobile 360 – Europe conference, where senior representatives from the mobile industry and regulatory bodies are convening to debate the future of telecoms in Europe.

“5G networks in Europe are expected to provide coverage to almost three-quarters of the region’s population by 2025 and Europe is set to become the world’s third-largest 5G market behind Asia Pacific and North America by this point,” commented Mats Granryd, Director General of the GSMA. “However, success in the 5G era will rest on the ability of governments to implement forward-looking regulatory frameworks that encourage sustainable investment, drive innovation and protect consumers.”

Mobile a Driver of Economic Growth in Europe

In 2017, mobile technologies and services generated 3.3 per cent of GDP1 in Europe, a contribution that amounted to EUR550 billion of economic value added. This contribution is expected to increase to EUR720 billion (4.1 per cent of GDP) by 2022. Europe’s mobile ecosystem also supported 2.5 million jobs in the region in 2017 and made a public funding contribution of EUR100 billion – mainly in the form of general taxation, including VAT, corporate taxes and employment taxes.

Reforms to Drive Digital Evolution

For Europe to realise the full potential of 5G, it needs to create a more supportive policy environment that positions it as a preferred location for investment. Regulation should seek to:

  • Encourage a strong pro-investment environment that will allow the mobile industry to make investments that will ultimately benefit consumers;
  • Support a policy of ‘same service, same rules’ that would lead to more competition, innovation and higher consumer welfare;
  • Provide timely access to harmonised spectrum in the right frequencies, at the right time, and under the right long-term conditions for operators to invest in future networks and services; and
  • Enable European operators to harness the full potential of data to innovate and compete globally while protecting the privacy and confidentiality of consumers

Europe Prepares to Move to 5G

Europe is the most highly penetrated regional mobile market in the world. According to today’s report, there were 465 million unique mobile subscribers2 in Europe at the end of 2017, representing 85 per cent of the population. This is forecast to grow to 481 million – 88 per cent of the population – by 2025.

Although there is still headroom for 4G growth in many markets, the first 5G launches by European mobile operators are anticipated by the end of the decade. By 2025, it is forecast that 5G will account for around 200 million connections, corresponding to a 29 per cent share of total connections in Europe.3

“Momentum is now building in Europe as we enter the 5G era, as mobile operators conduct trials and prepare to ramp up 5G investments over the coming years,” added Granryd. “Meanwhile, in light of ongoing financial and competitive pressures, Europe’s operators are looking beyond their core telco business in order to explore and unlock new revenue streams in both consumer and enterprise markets across a range of verticals.”

The new report ‘The Mobile Economy: Europe 2018’ is authored by GSMA Intelligence, the research arm of the GSMA. To access the full report and related infographics, please visit: www.gsma.com/mobileeconomy/europe/

-ENDS-

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators with over 350 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.

For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA .

1 GDP contribution includes direct mobile ecosystem contribution (0.9%); indirect contribution (0.5%); and productivity improvements (1.9%)

2 A unique mobile subscriber represents an individual that can account for multiple SIM connections

3 Excluding licenced cellular IoT connections

Contact:

For the GSMA Beau Bass +44 79 7662 4962 beau.bass@webershandwick.com or Olivier Lechien +32 479 99 01 63 olechien@gsma.com or GSMA Press Office pressoffice@gsma.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye